Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone415-365-5600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$49.87 million
Profitability
Miscellaneous
Employees209
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions
What is Five Prime Therapeutics' stock symbol?
Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."
How were Five Prime Therapeutics' earnings last quarter?
Five Prime Therapeutics Inc (NASDAQ:FPRX) issued its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported ($1.02) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.07) by $0.05. The biotechnology company earned $5.35 million during the quarter, compared to analysts' expectations of $5.71 million. Five Prime Therapeutics had a negative net margin of 683.89% and a negative return on equity of 54.87%. View Five Prime Therapeutics' Earnings History.
When is Five Prime Therapeutics' next earnings date?
What price target have analysts set for FPRX?
7 analysts have issued 1 year price targets for Five Prime Therapeutics' shares. Their predictions range from $10.00 to $44.00. On average, they anticipate Five Prime Therapeutics' stock price to reach $21.3333 in the next year. This suggests a possible upside of 281.6% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.
What is the consensus analysts' recommendation for Five Prime Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Five Prime Therapeutics.
Has Five Prime Therapeutics been receiving favorable news coverage?
Media stories about FPRX stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Five Prime Therapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View News Stories for Five Prime Therapeutics.
Who are some of Five Prime Therapeutics' key competitors?
Some companies that are related to Five Prime Therapeutics include Kiniksa Pharmaceuticals (KNSA), Arvinas (ARVN), Deciphera Pharmaceuticals (DCPH), Y-mAbs Therapeutics (YMAB), Emisphere Technologies (EMIS), CannTrust (CNTTF), Eagle Pharmaceuticals (EGRX), Omeros (OMER), Endo International (ENDP), Kura Oncology (KURA), Stoke Therapeutics (STOK), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), Advanz Pharma (CXRXF) and DiaMedica Therapeutics (DMCAF).
What other stocks do shareholders of Five Prime Therapeutics own?
Who are Five Prime Therapeutics' key executives?
Five Prime Therapeutics' management team includes the folowing people:
- Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)
- Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)
- Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)
- Dr. Peder K. Jensen, Advisor & Director (Age 64)
- Mr. David V. Smith, Exec. VP & CFO
Who are Five Prime Therapeutics' major shareholders?
Which institutional investors are buying Five Prime Therapeutics stock?
How do I buy shares of Five Prime Therapeutics?
Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Five Prime Therapeutics' stock price today?
One share of FPRX stock can currently be purchased for approximately $5.59.
How big of a company is Five Prime Therapeutics?
Five Prime Therapeutics has a market capitalization of $201.58 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.View Additional Information About Five Prime Therapeutics.
What is Five Prime Therapeutics' official website?
How can I contact Five Prime Therapeutics?
Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]
MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)
| Community Ranking: | | 2.8 out of 5 ( ) |
| Outperform Votes: | | 269 (Thanks for Voting!) |
| Underperform Votes: | | 213 (Thanks for Voting!) |
| Total Votes: | | 482 |
